OraSure Technologies (NASDAQ:OSUR) Rating Lowered to Hold at StockNews.com

StockNews.com lowered shares of OraSure Technologies (NASDAQ:OSUR) from a buy rating to a hold rating in a research report report published on Tuesday.

Separately, Evercore ISI cut their target price on OraSure Technologies from $7.00 to $6.50 and set an in-line rating for the company in a research report on Thursday, April 4th. Three analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of Hold and an average target price of $6.38.

OraSure Technologies Stock Down 4.4 %

Shares of NASDAQ:OSUR opened at $5.26 on Tuesday. The business has a 50 day moving average price of $6.35 and a 200 day moving average price of $6.80. OraSure Technologies has a twelve month low of $4.38 and a twelve month high of $8.45. The company has a market cap of $402.44 million, a price-to-earnings ratio of 7.31 and a beta of 0.15.

OraSure Technologies (NASDAQ:OSUR) last announced its earnings results on Tuesday, February 27th. The medical instruments supplier reported $0.22 earnings per share for the quarter, beating the consensus estimate of $0.13 by $0.09. OraSure Technologies had a return on equity of 14.50% and a net margin of 13.23%. The firm had revenue of $75.88 million during the quarter, compared to the consensus estimate of $74.13 million. During the same quarter in the prior year, the company earned $0.21 EPS. The firm’s revenue for the quarter was down 38.3% compared to the same quarter last year. Analysts anticipate that OraSure Technologies will post -0.11 EPS for the current year.

Hedge Funds Weigh In On OraSure Technologies

Hedge funds and other institutional investors have recently modified their holdings of the stock. AJOVista LLC acquired a new stake in OraSure Technologies during the 4th quarter valued at $39,000. Tocqueville Asset Management L.P. acquired a new stake in OraSure Technologies during the 3rd quarter valued at $75,000. Pathstone Family Office LLC acquired a new stake in OraSure Technologies during the 3rd quarter valued at $80,000. Dynamic Technology Lab Private Ltd acquired a new stake in OraSure Technologies during the 4th quarter valued at $113,000. Finally, Baader Bank Aktiengesellschaft acquired a new stake in OraSure Technologies during the 4th quarter valued at $115,000. Institutional investors own 93.50% of the company’s stock.

About OraSure Technologies

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.